Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma Clinical Trial

— SIRveNIB  

Official title:

Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01135056
• Other study ID #: AHCC06
• Status: Active, not recruiting
• Phase: Phase 3
• First received: May 24, 2010
• Last updated: April 22, 2018
• Start date: July 2010
• Est. completion date: July 31, 2018

Study information

• Verified date: April 2018
• Source: Singapore General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to assess the efficacy of SIRT as compared with Sorafenib in patients with locally advanced liver cancer in terms of overall survival (OS).

The Study null hypothesis is, there is no difference in overall survival between patients receiving SIRT and those receiving Sorafenib therapy.

Description:

Hepatocellular carcinoma (HCC) is the 5th most common cancer worldwide but unfortunately between 70 - 80% of all HCC are in the Asia-Pacific because of the prevalence of chronic viral hepatitis in the region. The increase in the prevalence of chronic hepatitis C in the Western world however predicts that HCC will similarly be an important cause of death there in the next 20 years.

Only 15-20% of HCC are today potentially curable by surgery at the time of diagnosis. Another 10-15% of patients may benefit from potentially curative locally ablative therapy such as radio-frequency ablation. Prognosis in the majority of patients has been dismal as conventional systemic therapies have been largely inefficacious. The first successfully trialed systemic targeted therapy, sorafenib (2007) prolonged survival by a modest average of 3 months in patients with good underlying liver function.

While the liver is radio-sensitive, external beam radiation causes significant radio-toxicity. To overcome this, selective internal radiation therapy (SIRT) was developed to deliver a radiation source directly to liver cancer via the arterial route. Sir-sphere is radioactive yttrium on a 90 micro-meter diameter resin carrier and is an established therapy in colorectal metastasis. Sir-sphere has been reported to cause significantly tumour regression in HCC.

This study will evaluate the efficacy of SIRT using SIR-Spheres yttrium-90 microspheres compared to sorafenib in the treatment of patients with locally advanced primary HCC.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 360
• Est. completion date: July 31, 2018
• Est. primary completion date: July 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Disease must be locally advanced as defined by BCLC (B) intermediate stage or BCLC (C) advanced stage without extra-hepatic disease (only with branch portal vein thrombosis).

• Willing, able and mentally competent to provide written informed consent prior to any testing undertaken for this study protocol, including screening tests and evaluations that are not considered to be part of the subject's routine care.

• Aged 18 years/older (either gender).

• Unequivocal diagnosis of HCC.

• HCC not amenable to surgical resection or immediate liver transplantation, or cannot be optimally treated with local ablative techniques such as RFA, consistent with the practice of the clinical trial centre.

• Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as = 10 mm with spiral CT scan or MRI.

• ECOG performance status 0-1.

• Child-Pugh A-B (up to 7 points)

• Adequate haematological, renal and hepatic function as follows:

• Leukocytes = 2,500/µL

• Platelets = 80,000/µL

• Haemoglobin > 9.5g/dL

• Total bilirubin < 2.0mg/dL

• INR = 2.0

• ALP = 5 x institutional ULN

• AST and ALT = 5 x institutional ULN

• Albumin = 2.5g/dL

• Creatinine = 2.0mg/dL

• Life expectancy of at least 3 months without any active treatment.

• Suitable for protocol treatment as determined by clinical assessment undertaken by the Investigator.

• Female patients must be either postmenopausal or, if premenopausal, must have a negative pregnancy test and agree to use 2 forms of contraception if sexually active during their study participation.

• Male patients must be surgically sterile, or if sexually active and having a pre-menopausal female partner then must be using an acceptable form of contraception.

Exclusion Criteria:

• Have had more than 2 administrations of hepatic artery directed therapy.

• Subjects who have had hepatic artery directed therapy done < 4 weeks prior to study entry.

• Have had systemic chemotherapy for HCC except for prior adjuvant or neoadjuvant therapy given more than 6 months from enrolment.

• have had prior treatment with Sorafenib or VEGF inhibitors.

• Prior hepatic radiation therapy for HCC or other malignancy.

• Currently receiving any other investigational agents for the treatment of their cancer.

• Has intractable clinical ascites (in spite of optimal diuretic treatment) or any other clinical signs of liver failure, on physical examination.

• Complete main portal vein thrombosis.

• Any metastatic disease (local-regional lymph nodes measuring less than 2 cm in greatest diameter or lung nodules measuring less than 1 cm are not contraindications as per Investigator discretion).

• Any other concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least 5 years.

• Presence of clinical signs of CNS metastases due to their poor prognosis and because progressive neurologic dysfunction would confound the evaluation of neurologic and other adverse events.

• Uncontrolled inter-current illness including, but not limited to, ongoing or active infection (except viral hepatitis), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Any of the following contraindications to angiography and selective visceral catheterization:

• Bleeding diathesis, not correctable by the standard forms of therapy.

• Severe peripheral vascular disease that would preclude arterial catheterization.

• Portal hypertension with hepato-fugal flow as documented on baseline spiral CT scan.

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to SIR-Spheres or Sorafenib.

• Inability or unwillingness to understand or sign a written informed consent document.

• Female subjects who are pregnant or currently breastfeeding.

• Female subjects, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception, as per Investigator discretion during the study. The rhythm method is not to be used as the sole method of contraception.

• Male subjects, unwillingness to practice effective contraception (per Investigator discretion) while taking part in this study, because the effect of the SIR-Spheres treatment on sperm or upon the development of an unborn child are unknown.

• Current enrolment in any other investigational therapeutic drug or device study.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Device:
• SIR-Spheres
One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.

Drug:
• Sorafenib tosylate
Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops

Locations

Country	Name	City	State
Brunei Darussalam	The Brunei Cancer Centre	Jerudong	Brunei
China	Queen Mary Hospital	Hong Kong	Hong Kong
Indonesia	University of Udayana, Rumah Sakit Sanglah, Indonesia	Denpasar	Bali
Indonesia	Cipto Mangunkusumo Hospital ,University of Indonesia	Jakarta
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Korea University Anam Hospital	Seoul
Korea, Republic of	Seoul National University Bundang Hospital	Seoul
Korea, Republic of	Seoul St. Mary's Hospital	Seoul
Korea, Republic of	Severance Hospital, Yonsei University College of Medicine	Seoul
Malaysia	University Malaya Medical Center	Kuala Lumpur
Malaysia	Sarawak General Hospital	Kuching	Sarawak
Malaysia	Penang Adventist Hospital	Penang
Mongolia	National Cancer Center of Mongolia	Ulaanbaatar
Myanmar	Yangon GI & Liver Centre	Yangon
New Zealand	Auckland City Hospital	Grafton	Auckland
Philippines	Davao Doctors Hospital	Davao
Philippines	Makati Medical Center	Manila	Makati City
Philippines	The Medical City	Pasig City	Manila
Philippines	St. Luke's Medical Center, Philippines	Quezon City	Manila
Singapore	Khoo Teck Puat Hospital	Singapore
Singapore	National Cancer Center Singapore	Singapore
Singapore	National University Hospital	Singapore
Singapore	Singapore General Hospital	Singapore
Taiwan	Kaohsiung Chang Gung Memorial Hospital	Kaohsiung
Taiwan	China Medical University Hospital	Taichung
Taiwan	National Taiwan University Hospital	Taipei City	Taipei
Taiwan	Taipei Veterans General Hospital	Taipei City	Taipei
Taiwan	Chang Gung Memorial Hospital	Taoyuan	Taoyuan Hsien
Thailand	Chulabhorn Hospital	Bangkok

Sponsors (5)

Lead Sponsor	Collaborator
Singapore General Hospital	National Cancer Centre, Singapore, National Medical Research Council (NMRC), Singapore, Singapore Clinical Research Institute, Sirtex Medical

Countries where clinical trial is conducted

Brunei Darussalam,  China,  Indonesia,  Korea, Republic of,  Malaysia,  Mongolia,  Myanmar,  New Zealand,  Philippines,  Singapore,  Taiwan,  Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	Overall Survival is defined as the time from the date of randomisation to the date of death due to any cause. All patients will be followed up until death to compare the overall survival between the two treatments. 2 years is an estimated time frame.	2 years
Secondary	Progression free survival in the liver	Progression-free survival in the liver is defined as the time interval between randomisation and the date of tumour progression in the liver or death, whichever is earlier. Tumour progression in the liver will be determined from serial CT scans. Diagnosis of tumour progression of disease should be made using the RECIST guideline version 1.1. 2 years is an estimated time frame.	2 years
Secondary	Progression free survival overall	Progression-free survival overall is defined as the time interval between randomisation and the date of tumour progression at any site in the body or death, whichever is earlier. Tumour progression at any site in the body will be measured by any definitive imaging technique including CT scan, MRI study or other nuclear medicine scan. The Investigator should clearly indicate the site of tumour progression (hepatic or extra-hepatic) at the time of recurrence.; 2 years is an estimated time frame.	2 years
Secondary	Tumour Response Rate	Tumour response and progression will be evaluated in this study using the new response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [European Journal of Cancer (45): 228 - 247, 2009] (http://ctep.cancer.gov/protocolDevelopment/docs/recist_guideline.pdf).; 2 years is an estimated time frame	2 years
Secondary	Toxicity and Safety	Toxicity will be assessed using the National Cancer Institute Common Terminology Criteria (NCI-CTC) version 4.02. Patients for both treatment arms will be followed-up for safety and toxicity from the time of study entry (randomisation day) until 30 days post study conclusion or until commencement of the next alternative therapy, which ever is earlier.	Up to 2 years
Secondary	Health Related Quality of Life (QoL)	Quality of life (QoL) will be measured by using the EQ-5D questionnaire over the study period. QoL for patients will be measured until their first disease progression up to 2 years (estimated) which ever is earlier.	Up to 2 years
Secondary	Liver resection rate	Patients will be assessed for suitability for liver resection every 12 weekly until their study conclusion up to 2 years which ever is earlier.	Up to 2 years
Secondary	Liver Transplantation Rate	Patients will be assessed for suitability for liver transplantation every 12 weekly until their study conclusion up to 2 years which ever is earlier.	Up to 2 years
Secondary	Time to Disease Progression	Time to Disease Progression (TTP) is defined as a measure of time after a disease is diagnosed (or treated) until the disease starts to get worse. Disease Progression will be measured by RECIST guideline version 1.1. TTP will be measured every 12 weekly up to 2 years (estimated).	Up to 2 years
Secondary	Disease control rate		2 years

External Links

•   AHCC Trials Group
•   AHCC06 Study Website